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Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved ser-
ine/threonine protein kinase encoded in mammals by two genes that generate two related
proteins: GSK-3α and GSK-3β. GSK-3 is active in cells under resting conditions and is pri-
marily regulated through inhibition or diversion of its activity. While GSK-3 is one of the
few protein kinases that can be inactivated by phosphorylation, the mechanisms of GSK-3
regulation are more varied and not fully understood. Precise control appears to be achieved
by a combination of phosphorylation, localization, and sequestration by a number of GSK-3-
binding proteins. GSK-3 lies downstream of several major signaling pathways including the
phosphatidylinositol 3′ kinase pathway, the Wnt pathway, Hedgehog signaling and Notch.
Speciﬁc pools of GSK-3, which differ in intracellular localization, binding partner afﬁnity,
and relative amount are differentially sensitized to several distinct signaling pathways and
these sequestration mechanisms contribute to pathway insulation and signal speciﬁcity.
Dysregulation of signaling pathways involving GSK-3 is associated with the pathogenesis
of numerous neurological and psychiatric disorders and there are data suggesting GSK-3
isoform-selective roles in several of these. Here, we review the current knowledge of GSK-
3 regulation and targets and discuss the various animal models that have been employed
to dissect the functions of GSK-3 in brain development and function through the use of
conventional or conditional knockout mice as well as transgenic mice. These studies have
revealed fundamental roles for these protein kinases in memory, behavior, and neuronal
fate determination and provide insights into possible therapeutic interventions.
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CHARACTERIZATION OF GSK-3
Glycogen synthase kinase-3 (ATP:protein phosphotransferase,
E.C. 2.7.1.37) is a serine/threonine protein kinase, belonging to
the CMCG family of proline-directed kinases (Cyclin-dependent
kinases (CDKs), Mitogen-activated protein kinases (MAPKs),
Glycogen synthase kinases (GSKs), and CDK-like kinases (CLKs).
GSK-3 is a monomeric, second messenger-independent protein
kinase that was ﬁrst discovered through its ability to activate the
ATP–Mg-dependent form of type-1 protein phosphatase (“Factor
A”) and to phosphorylate the key rate-limiting metabolic enzyme
that catalyzes the last step of glycogen synthesis, glycogen synthase
(GS; Embi et al., 1980; Rylatt et al., 1980;Vandenheede et al., 1980).
GSK-3 is a highly conserved protein kinase and has orthologs
in plants, fungi, worms, ﬂies, sea squirts, and vertebrates: isoen-
zymes from species as distant as ﬂies and humans display more
than 90% sequence similarity within the protein kinase domain
(reviewed in Ali et al., 2001). GSK-3/FA has been puriﬁed by sev-
eral groups (Hemmings et al., 1982; Woodgett and Cohen, 1984;
Tung and Reed, 1989), and was molecularly cloned based on par-
tial peptide sequencing (Woodgett, 1990). Two rat brain cDNAs
encoding GSK-3 were isolated that corresponded to isoenzymes
designated GSK-3 alpha(α) and GSK-3 beta(β), with apparent
M r of 51,000Da (483 aa in humans) and 47,000Da (433 aa),
respectively (Woodgett, 1990). Genes encoding GSK-3α and β are
located on mouse chromosome 7/human chromosome 19 and on
mouse chromosome 16/human chromosome 3, respectively (see
Figure 1; based onhttp://genome.ucsc.edu).MammalianGSK-3 is
therefore represented by two paralogous proteins. Overall, GSK-
3α and β share 85% overall sequence homology, including 98%
amino acid sequence identity within their kinase domains (Wood-
gett, 1990). This latter fact makes the likelihood of development of
small molecule inhibitors that can discriminate the two forms very
unlikely. Despite their catalytic domain similarity, GSK-3 isoen-
zymes diverge in their N- and C-termini. For example, the two
gene products share only 36% identity in the last 76 C-terminal
residues (Woodgett, 1990). GSK-3α has an extended glycine-rich
N-terminal region that has been proposed to function as a pseu-
dosubstrate (Dajani et al., 2001). Interestingly, while many species
such as ﬁsh, amphibians, and lizards harbor both isoforms, birds
have onlyGSK-3β and appear to have selectively lostGSK-3α (Alon
et al., 2011).
GSK-3 is expressed ubiquitously and both gene products are
found in virtually all mammalian tissues. The kinase is highly
expressed in the brain (Woodgett, 1990; Yao et al., 2002; Perez-
Costas et al., 2010), both in neurons and glia (Ferrer et al., 2002).
In the developing brain, the presence of GSK-3 is high at E18 and
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FIGURE 1 | Intron/exon structure of the two mammalian GSK-3 genes indicating the differential splice of GSK-3β and location of LoxP recombination
sites in conditional alleles.
peaks at P8, decreasing somewhat after that period (Takahashi
et al., 1994). In adult brain, GSK-3α is especially abundant in the
hippocampus, cerebral cortex, striatum, and cerebellum (based on
Allen Brain Atlas). GSK-3β is expressed in nearly all brain regions,
although there are marked regional differences of GSK-3βmRNA
levels in the human brain (Pandey et al., 2009). As a caution,
the glycine-rich (and hence purine-rich) region of GSK-3α may
distort comparative analysis of RNA expression between it and
GSK-3β.
In certain cell types of the brain, alternative splicing between
exon 8 and 9 of GSK-3β leads to the generation of an additional
“long” form containing a 13 amino acid insert within the catalytic
domain (GSK-3β2; see Figure 1). This insert is located between
residues 303 and 304 of GSK-3β, and is ﬂanked by two proximal α-
helices of kinase subdomains X and XI (Hanks and Hunter, 1995;
Mukai et al., 2002). This alternatively spliced isoform of GSK-3β
in rodents (Mukai et al., 2002; Yao et al., 2002) and in human (Lau
et al., 1999; Schaffer et al., 2003; Kwok et al., 2005) has been impli-
cated in neuronal-speciﬁc functions. The short form of GSK-3β
is ubiquitously expressed in the body, including the developing
and adult nervous system (Takahashi et al., 1994; Leroy and Brion,
1999). By contrast, GSK-3β2 is predominantly expressed in the
neural tissues, with highest levels in the developing brain and per-
sistence into adulthood (Mukai et al., 2002; Wood-Kaczmar et al.,
2009).
GSK-3 REGULATION
An unusual feature of GSK-3 is that the kinase displays high
activity in cells under resting/unstimulated conditions (Suther-
land et al., 1993; Stambolic and Woodgett, 1994; Woodgett, 1994)
and is one of few protein kinases that is inhibited by extracellular
signals that induce a rapid and reversible increase in serine phos-
phorylation of GSK-3 causing a decrease in enzymatic activity.
For example, growth factor, insulin, or serum treatment decreases
GSK-3 activity by 30–70% within 10min (Sutherland et al., 1993;
Welsh and Proud, 1993; Saito et al., 1994; Stambolic andWoodgett,
1994; Sutherland and Cohen, 1994; Cross et al., 1995; Eldar-
Finkelman et al., 1995). The mechanisms of GSK-3 regulation are
varied and not yet fully understood; precise control appears to be
achieved by a combination of phosphorylation, localization, and
sequestration by a number of GSK-3-binding proteins (reviewed
in Frame and Cohen, 2001; Doble and Woodgett, 2003; Jope and
Johnson, 2004; Kockeritz et al., 2006).
REGULATION THROUGH PHOSPHORYLATION
GSK-3 is dual speciﬁcity kinase differentially regulated by tyro-
sine and serine/threonine phosphorylation. The activity of GSK-3
is positively regulated by phosphorylation on a “T loop” tyrosine
residuewithin subdomainVIII (Tyr279 forGSK-3α andTyr216 for
GSK-3β; Hughes et al., 1993; Lochhead et al., 2006). The kinase
is negatively regulated by N-terminal phosphorylation of serine
residues of the enzyme (Ser21 for GSK-3α and Ser9 for GSK-
3β; Sutherland et al., 1993; Sutherland and Cohen, 1994). p38
MAPK can also inactivate GSK-3β via phosphorylation within its
C-terminal region at Ser389 and Thr390 (Thornton et al., 2008).
p38 MAPK-mediated phosphorylation of GSK-3β occurs primar-
ily in the brain and thymocytes (Thornton et al., 2008). In addition,
Thr43 of GSK-3β may be phosphorylated by Erk, resulting in
GSK-3 inhibition (Ding et al., 2005).
From the crystal structure, it has been proposed that unphos-
phorylated Tyr276/Tyr216 act to block the access of primed sub-
strates (as discussed below). Indeed, the structure of phosphory-
lated GSK-3β (Bax et al., 2001) shows that phosphorylated Tyr216
undergoes a conformational change that allows substrates to bind
the enzyme. Previous studies, however, led to conﬂicting conclu-
sions as towhether tyrosine phosphorylation of GSK-3 is catalyzed
by GSK-3 itself (autophosphorylation) or by a distinct tyrosine
kinase (Hughes et al., 1993; Kim et al., 1999; Lesort et al., 1999;
Frontiers in Molecular Neuroscience www.frontiersin.org November 2011 | Volume 4 | Article 40 | 2
Kaidanovich-Beilin and Woodgett Regulation and functions of GSK-3 in the brain
Wang et al., 2003; Cole et al., 2004a). In support of the autophos-
phorylation model, at least in mammals, Lochhead et al. (2006)
showed that newly synthesized GSK-3β autophosphorylated itself
on tyrosine and that this event could be prevented by exposure to
GSK-3 inhibitors.
In contrast to tyrosine phosphorylation, regulation of N-
terminal serine phosphorylation is only conserved in GSK-3
homologs from mammals, Xenopus, and Drosophila, but not in
yeast, higher plants, Dictyostelium, or Caenorhabditis elegans. The
phosphorylation state of serine residues of both isoenzymes is
dynamic, involving phosphorylation by several protein kinases
and dephosphorylation by protein phosphatase-1 (PP-1; Suther-
land et al., 1993; Saito et al., 1994; Stambolic and Woodgett, 1994;
Cross et al., 1995; Eldar-Finkelman et al., 1995; Welsh et al., 1998;
Zhang et al., 2003). N-terminal domain serine phosphorylation of
GSK-3α and GSK-3β leads to inhibition of its activity (Suther-
land et al., 1993; Saito et al., 1994; Stambolic and Woodgett,
1994; Cross et al., 1995; Eldar-Finkelman et al., 1995; Welsh et al.,
1998; Grimes and Jope, 2001; Zhang et al., 2003). Phosphorylation
of GSK-3 within its N-terminal region creates a “pseudosub-
strate”which intramolecularly binds to a“phosphoprotein binding
pocket”within the active site of the kinase, suppressing activity by
occluding primed substrate access to the binding pocket (Frame
et al., 2001).
This inhibitory mechanism is induced by agonists such as neu-
rotrophins and growth factors that activate protein kinases that
act on the N-terminal domain of GSK-3 such as PKB/Akt, p90rsk,
cyclic-AMP-dependent protein kinase, p70 S6 kinase, as well as
regulators of phosphatase-1 (Sutherland et al., 1993; Stambolic
andWoodgett, 1994;Alessi et al., 1996; Li et al., 2000; Svenningsson
et al., 2003; see Figure 2). For example, insulin leads to inhibition
of GSK-3 via insulin receptor substrate-1-dependent induction
of phosphatidylinositol 3′ kinase (PI3K), which then stimulates
PKB/Akt (Cross et al., 1995). GSK-3 has previously been shown
to catalyze serine phosphorylation of IRS-1 and IRS-2, inter-
fering with receptor-mediated tyrosine phosphorylation by the
insulin receptor, effectively attenuating insulin receptor signaling
via a negative feedback loop (Eldar-Finkelman and Krebs, 1997;
Sharﬁ and Eldar-Finkelman, 2008; Figure 2). Moreover, recent
studies have revealed novel bi-directionality in the interaction of
PKB/Akt and GSK-3 whereby genetic ablation of GSK-3 signiﬁ-
cantly suppresses PKB/Akt phosphorylation (Lu et al., 2011), indi-
cating a possible novel feedback loop in PKB/Akt/MAPK network
(Figure 2).
Growth factors, such as EGF and PDGF can also inhibit GSK-3
activity through thephosphatidylinositol 3′ kinase (PI3K)pathway
(Stambolic andWoodgett, 1994; Shaw and Cohen, 1999), as well as
through induction of the MAPK cascade (Saito et al., 1994; Brady
et al., 1998). Ser9/21 phosphorylation of GSK-3 canbemodiﬁed by
amino acid deprivation through mammalian target of rapamycin
(mTOR; Armstrong et al., 2001; Krause et al., 2002; Terruzzi et al.,
2002) or in response to agonists that elevate the intracellular lev-
els of cAMP through cyclic-AMP-dependent protein kinase (PKA;
Fang et al., 2000; Li et al., 2000; Figure 2). The PKA-anchoring
FIGURE 2 | Summary of regulatory signaling inputs into GSK-3.
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protein 220 binds both GSK-3 and PKA and hence facilitates GSK-
3 phosphorylation by this protein kinase (Tanji et al., 2002). PKC
agonists can also regulate GSK-3 (Ballou et al., 2001; Fang et al.,
2002), however certain PKCs may preferentially regulate GSK-3β
but not GSK-3α (Goode et al., 1992).
REGULATION THROUGH COMPLEX FORMATION
Wnts are secreted glycolipoproteins that activate canonical and
non-canonical (β-catenin independent) Wnt signaling cascades,
which are essential for early embryonic patterning, cell fate, cel-
lular polarity, cell movement, cell proliferation as well as adult
homeostasis in both vertebrates and invertebrates (Logan and
Nusse, 2004; Moon et al., 2004; Salinas, 2005; MacDonald et al.,
2009). The canonical Wnt signaling pathway employs a dis-
tinct mechanism for regulating GSK-3 that is independent of
N-terminal domain serine phosphorylation or tyrosine phospho-
rylation and, instead, relies on protein:protein interactions and
intracellular sequestration. Thus, the canonicalWnt pathway com-
prises phylogenetically conserved proteins: theWnt receptor, Friz-
zled; co-receptor, low-density lipoprotein receptor-related protein
(LRP) 5/6; scaffolding proteins, Disheveled (Dvl), Axin, Adeno-
matous polyposis coli (APC) and GSK-3, β-catenin, and casein
kinase-1 (CK1; see Figure 3).
In cells a small fraction (<5–10%) of cellular GSK-3 is asso-
ciated with a scaffolding protein termed Axin (Lee et al., 2003;
Benchabane et al., 2008). These molecules are joined by others
to create a “destruction complex” comprising Axin, APC, CK1,
GSK-3, and β-catenin (Zeng et al., 1997; Hart et al., 1998; Ikeda
et al., 1998). Within this machine, CK1 phosphorylates Ser45 of
β-catenin, which generates a priming site for subsequent GSK-3
phosphorylation on Thr41 (Amit et al., 2002; Hagen and Vidal-
Puig, 2002; Hagen et al., 2002; Liu et al., 2002; Sakanaka, 2002;
Yanagawa et al., 2002) and subsequently Ser37 and Ser33; result-
ing in β-catenin recognition by β-TrCP (an E3 ubiquitin ligase
subunit), and subsequent ubiquitin-mediated proteasomal degra-
dation of β-catenin (Aberle et al., 1997; Amit et al., 2002; Liu
et al., 2002; He et al., 2004). This results in the maintenance of
very low levels of β-catenin within the cytoplasm and nucleus of
cells (signiﬁcant amounts of β-catenin are associated, in epithe-
lial cells, with the cadherin adhesion molecules but this fraction is
effectively sequestered and does not play a role in Wnt signaling).
In addition to β-catenin, both Axin and APC are phosphorylated
by GSK-3. Phosphorylation of Axin by GSK-3 increases its sta-
bility and binding to β-catenin (Ikeda et al., 1998; Jho et al.,
1999; Yamamoto et al., 1999). Phosphorylation of APC increases
its afﬁnity to β-catenin (Rubinfeld et al., 1996). Both events
promote β-catenin phosphorylation and degradation complex
stability.
Wnt ligand induces binding of the seven-pass transmembrane
receptor Frizzled and the LRP5/6 co-receptor which leads to the
recruitment of Dvl and induction of LRP 5/6 phosphorylation
by GSK-3 and CK1. This creates a high afﬁnity binding site for
Axin (He et al., 2004; Zeng et al., 2005; Mi et al., 2006; Niehrs and
Shen, 2010). Recruitment of Axin to the receptor proteins results
in functional dissolution of the destruction complex allowing the
stabilization and accumulation of β-catenin. The now stable β-
catenin translocates to the nucleus where it binds with members
of the TCF/LEF family of DNA-binding proteins, resulting in
transcriptional activation of certain targets genes.
β-catenin is dephosphorylated primarily by protein phos-
phatase (PP) 2A (Su et al., 2008).APCmay also act to interferewith
PP2A dephosphorylation of β-catenin (Su et al., 2008). APC also
facilitates Axin degradation (Lee et al., 2003; Takacs et al., 2008).
PP-1 activity leads to dephosphorylation of Axin, antagonizing
CK1 phosphorylation as well as negatively regulating GSK-3-Axin
binding, promoting complex disassembly (Luo et al., 2007).
Several molecular mechanisms have been proposed to explain
how canonical Wnt signaling may interfere with GSK-3-
dependent phosphorylation of β-catenin (reviewed in Kimelman
and Xu, 2006). For example, the intracellular domain of LRP6 may
act as a direct inhibitor of GSK-3 (Mi et al., 2006; Cselenyi et al.,
2008; Piao et al., 2008; Wu et al., 2009). A recent study suggested
an important role of multi-vesicular endosomes in the canonical
Wnt pathway (Taelman et al., 2010). In cells harboring a consti-
tutively activated mutant of LRP6, sequestration of GSK-3 into
these membrane-bound organelles was observed, leading to insu-
lation of GSK-3 from other components of the pathway (Taelman
et al., 2010). This trafﬁcking machinery required β-catenin which
formed a feed-forward loop by facilitating GSK-3 sequestration
(Taelman et al., 2010). Whether this mechanism plays a role in
physiological Wnt signaling has yet to be determined.
Both mammalian isoforms of GSK-3 function equivalently in
Wnt signaling and are entirely redundant (Doble et al., 2007).
Indeed, retention of just one of the four GSK-3 alleles is sufﬁcient
to maintain low levels of β-catenin in the absence of Wnt, reiterat-
ing the fact that only a small fraction of GSK-3 is tightly associated
with Axin and therefore relevant to Wnt signaling.
GSK-3 can also associate with other proteins, e.g., GSK-3-
binding protein (GBP or FRAT; Li et al., 1999; Fraser et al., 2002)
and GSKIP (Chou et al., 2006); however, the roles of FRAT and
GSKIP in GSK-3 biology have yet to be deﬁned. GSK-3 is also
a part of interacting complex of proteins involved in Hedge-
hog (Hh) pathway, regulating a key transcription factor of Hh
signaling – cubitus interruptus (Ci; Price and Kalderon, 2002).
REGULATION THOUGH INTRACELLULAR LOCALIZATION
In addition to binding proteins in the cytoplasm, there are differ-
ences in patterns of subcellular localization of the GSK-3 isozymes
(Hoshi et al., 1995; Franca-Koh et al., 2002; Bijur and Jope, 2003).
GSK-3 is largely considered as a cytoplasmic protein,but the kinase
can also be detected in the nucleus and mitochondria where it is
more active compared with the larger cytoplasmic fraction (Bijur
and Jope, 2003). Nuclear localization of GSK-3 is dynamic and
dependent on the cell cycle (being highest during S-phase; Diehl
et al., 1998). Activity is also rapidly increased during apoptosis
(Bijur and Jope, 2001). The mechanisms governing intracellular
localization of GSK-3 are not fully elucidated. Activated PKB/Akt
has been reported to decrease nuclear levels of GSK-3 (Bijur
and Jope, 2001). Binding of FRAT 1 to GSK-3 facilitates nuclear
export (Franca-Koh et al., 2002). The viral tumor-associated latent
nuclear antigen binds GSK-3 and acts to enrich it in the nuclear
fraction (Fujimuro et al., 2003). As mentioned previously, GSK-
3α has an N-terminal extension compared to GSK-3β. One role
of this extra domain may be to provide a level of regulation to
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FIGURE 3 | Interaction between different intracellular pools of GSK-3 and protein complexes, involved intoWnt, Hedgehog (Hh), GCPR, and
PAR3/6–Cdc42–PKC pathways. (A); resting conditions. (B); activated conditions.
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nuclear transport of this isoform (Azoulay-Alfaguter et al., 2011).
Notably, deletion of N-terminus of GSK-3 beta reduces its nucleus
accumulation (Meares and Jope, 2007). These studies indicate that
at least a fraction of GSK-3 may be regulated by intracellular
compartmental shuttling.
The ﬁnding that GSK-3 acts downstream of multiple signaling
pathways that have distinct effects on cells and tissues presents a
conundrum. How might signal selectivity be achieved if a protein
common to multiple pathways was a required intermediary? The
elegant cellular solution to this is to fractionate GSK-3 between
scaffolding proteins or other structures such that each system
has its own population of GSK-3 molecules “assigned” to it. This
effectively insulates the signals and requires that the GSK-3 sub-
populations do not intermingle or exchange. It is still an open
question why so many important pathways evolved with a com-
mon component, a subject of speculative commentary (McNeill
and Woodgett, 2010).
GSK-3 SUBSTRATES
The determination of the crystal structure of GSK-3β provided
further insight into themolecular nature of the regulation of GSK-
3 and its predilection for primed, pre-phosphorylated, substrates
(Dajani et al., 2001; ter Haar et al., 2001). GSK-3 shares common
featureswith other protein kinases and has a smallN-terminal lobe
mostly consisting of β-sheets and a large C-terminal lobe essen-
tially formed of α-helices (Noble et al., 2005). The ATP-binding
pocket is located between the two lobes and is so highly con-
served between the two isoforms that discrimination between the
two protein kinases by an ATP analog-based inhibitor is highly
unlikely (Bain et al., 2007).
GSK-3 is one of only a handful of the over 500 known pro-
tein kinases that has a strong (500- to 1000-fold) preference for
substrates that are already primed by phosphorylation at a prox-
imal serine/threonine to the GSK-3 target residue (Thomas et al.,
1999). The phosphorylated residue within the presumptive sub-
strate slots into to a “phosphate-binding” pocket that comprises
three crucial basic residues – Lys205, Arg96, and Arg180 (Bax
et al., 2001; Dajani et al., 2001; ter Haar et al., 2001). These three
residues are conserved in all GSK-3 homologs identiﬁed to date,
suggesting conservation of the priming phosphate-binding site
and the substrate speciﬁcity of GSK-3 in all organisms. Bind-
ing of the priming phosphate of the substrate to this pocket on
GSK-3 induces a conformational change, aligning the substrate
for subsequent phosphorylation.
The majority of GSK-3 substrates exhibit an absolute require-
ment for prior phosphorylation by another kinase at a “priming”
residue located C-terminal to the site of subsequent phosphory-
lation by GSK-3 (Fiol et al., 1987). GSK-3-catalyzed phosphory-
lation of these substrates occurs at the fourth (Fiol et al., 1990)
or ﬁfth (Cole et al., 2006) serine or threonine residue N-terminal
to the primed site (pS/T1XXXpS/T2), where the ﬁrst pS/T1 (Ser
or Thr) is the target residue, X is any amino acid (but often
Pro), and the last pS/T2 is the site for priming phosphoryla-
tion. Thus, the primed Ser/Thr is recognized by the positively
charged “binding pocket” on GSK-3 which facilitates the correct
orientation of the substratewithin the active site of the kinase. Sev-
eral protein kinases have been shown to act as priming enzymes
for GSK-3 phosphorylation, including CDK-5 (Sengupta et al.,
1997; Noble et al., 2003; Li et al., 2006), PAR-1 (Nishimura et al.,
2004), casein kinase-1 (Amit et al., 2002), casein kinase-2 (Pic-
ton et al., 1982; DePaoli-Roach et al., 1983), PKA (Singh et al.,
1995), and PKC (Liu et al., 2003). In the case of several sub-
strates, the residue phosphorylated by GSK-3 acts to prime an
additional Ser/Thr residue N-terminal to it. This can lead to a
zippering effect where multiple residues become phosphorylated
by GSK-3. Certain substrates apparently dodge the requirement
for prior phosphorylation including c-Jun (Boyle et al., 1991), c-
Myc (Saksela et al., 1992), histone H1.5 (Happel et al., 2009), and
MARK2/PAR-1 (Kosuga et al., 2005; Timm et al., 2008). In these
cases, acidic residues or peptide conformations may substitute for
the effect of the priming phosphate.
To prove that an in vitro identiﬁed protein is an in vivo physi-
ological substrate of GSK-3 the target has to meet several criteria
(Frame and Cohen, 2001). These include phosphorylation of the
protein at the appropriate residues by the protein kinase in vitro
and under conditions known to modulate that kinase in vivo and
selective reduction in those phosphorylation sites upon treatment
with a speciﬁc inhibitor of the protein kinase (or via gene knock-
out/RNAi). To date, over 100 cytoplasmic and nuclear proteins
have been identiﬁed as substrates of GSK-3 although not all of
these meet the Frame and Cohen criteria as bona ﬁde targets
(reviewed in Doble and Woodgett, 2003; Jope and Johnson, 2004;
Kockeritz et al., 2006; Sutherland, 2011; see Table 1).
With respect to biological processes, GSK-3 substrates may
be classiﬁed into several groups of proteins/transcriptional fac-
tors/regulatory enzymes that have roles in processes such as
metabolism, cellular architecture, gene expression, neurobiolog-
ical processes, synaptogenesis, neurodevelopment, axonal growth
and polarity, immune response, circadian rhythms, and neu-
ronal/cellular survival (reviewed in Frame andCohen, 2001;Doble
andWoodgett, 2003; Jope and Johnson,2004;Kockeritz et al., 2006;
Sutherland, 2011; see Table 1).
GSK-3 SUBSTRATES RELATED TO CIRCADIAN RHYTHMS
Circadian (from the Latin circa diem meaning “about a day”)
rhythms occur with a periodicity of about 24 h and enable organ-
isms to adapt and anticipate environmental changes. Circadian
control provides an evolutionary advantage to organisms in adapt-
ing their behavior and physiology to the appropriate time of day
(reviewed in Wijnen and Young, 2006; Sahar and Sassone-Corsi,
2009). Feeding behavior, sleep-wake cycles, hormonal levels, and
body temperature are just a few examples of physiological circa-
dian rhythms. Dysregulation of the cycle is associated with the
onset and development of numerous human diseases, including
sleep disorders, depression, and dementia.
From a molecular standpoint, circadian rhythms are regulated
by transcriptional and post-translational feedback loops gener-
ated by a set of interplaying “clock” proteins. The positive limb
of the mammalian clock machinery is comprised of CLOCK
and BMAL1, which are transcription factors that heterodimerize
through their PAS domains and induce the expression of clock-
controlled genes by binding to their promoters at E-boxes. Cryp-
tochromes (Cry 1, Cry2) and Period genes (Per1, Per2, Per3)
are clock-controlled genes that encode proteins that form the
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Table 1 | GSK-3 substrates.
Substrate name GSK-3′s
phosphorylation site
(in bold) S/TxxxS/T
Biological process/relevance
to disease
Reference
METABOLIC ENZYMESAND SIGNALING PROTEINS
ATP-citrate lyase T446xxxS450xxxS454 Fatty acid biosynthesis Hughes et al. (1992), Benjamin et al. (1994)
Glycogen synthase S640xxxS644 Glycogen metabolism, diabetes Rylatt et al. (1980), Parker et al. (1983), Dent
et al. (1989)xxxS648xxx
S652xxxS656
Pyruvate dehydrogenase . . .?... Metabolism Hoshi et al. (1996)
Phosphocholine
cytidylyltransferase (CTP)
C-terminus CDP-choline pathway Cornell et al. (1995)
. . .?...
κ-casein . . .?... Milk protein Donella-Deana et al. (1983)
Protein phosphatase-1
G-subunit
S38xxxS42xxxS46 Signaling/protein dephosphorylation Dent et al. (1989)
Protein phosphatase
inhibitor-2
T72xxxS86 Signaling/protein dephosphorylation Aitken et al. (1984), DePaoli-Roach (1984)
Axin S322xxxS326xxxS330 Wnt pathway, development, cancer Ikeda et al. (1998), Jho et al. (1999),
Yamamoto et al. (1999)
Axil . . .?... Member of axin family Yamamoto et al. (1998)
Adenomatous polyposis
coli (APC)
S1501xxxS1505 Wnt pathway, development, cancer Rubinfeld et al. (1996), Ikeda et al. (2000),
Ferrarese et al. (2007)S1503xxxS1507
Cubitus interruptus/Gli S852xxxS856 Hedgehog pathway, development, cancer Jia et al. (2002), Price and Kalderon (2002)
S884xxxS888xxxS892
elF2B (Eukaryotic initiation
factor 2B)
S535xxxS539 Growth, cancer Welsh et al. (1998), Wang et al. (2001),
Woods et al. (2001)
Amyloid precursor protein
(APP)
T743xxx? Neuronal function, Alzheimer’s disease Aplin et al. (1996)
T668xxx?
Presenilin-1 S397xxxS401xxx? Alzheimer’s disease Kirschenbaum et al. (2001), Twomey and
McCarthy (2006)S353xxxS357xxx?
Heterogeneous nuclear
ribonucleoprotein D
S83xxxS87 Transcriptional regulator Tolnay et al. (2002)
Phosphatase interactor
targeting protein K (PITK)
S1013xxxS1017 PP-1 targeting subunit, modulates
phosphorylation of hnRNP K
Kwiek et al. (2007)
p21 CIP1 T57xxx? Cell cycle, apoptosis Rössig et al. (2002)
Insulin receptor
substrate 1
S332xxxS336 Diabetes, growth, cancer Eldar-Finkelman and Krebs (1997), Liber-
man and Eldar-Finkelman (2005)
Insulin receptor
substrate 2
S484xxxS488 Diabetes Sharﬁ and Eldar-Finkelman (2008)
P75 NGF receptor . . .?... Neurotrophin signaling Taniuchi et al. (1986)
Mcl-1 S140xxxT144 Growth, apoptosis, cancer Maurer et al. (2006), Ding et al. (2007)
Cyclic-AMP-dependent
protein kinase – RII subunit
S44xxS47xxx? cAMP pathway, hormonal responses Hemmings et al. (1982)
Cyclin D1 T286xxx? Cell cycle, cancer Diehl et al. (1998)
Cyclin E T380xxx? Cell cycle Welcker et al. (2003)
Myelin basic protein T97xxx? Myelination of nerves in CNS Yu andYang (1994)
Cry2 S553xxxS557 Circadian rhythm Harada et al. (2005), Kurabayashi et al.
(2010)
Per2 . . .?... Circadian rhythm Kaladchibachi et al. (2007)
Nucleoporin p62 C-terminus Cell division Miller et al. (1999)
. . .?...
PTEN (phosphatase and
tensin homolog)
S362xxxS366xxxS370 Cell proliferation, migration and growth, cell
survival
Al-Khouri et al. (2005)
(Continued)
Frontiers in Molecular Neuroscience www.frontiersin.org November 2011 | Volume 4 | Article 40 | 7
Kaidanovich-Beilin and Woodgett Regulation and functions of GSK-3 in the brain
Table 1 | Continued
Substrate name GSK-3′s
phosphorylation site
(in bold) S/TxxxS/T
Biological process/relevance
to disease
Reference
Lipoprotein
receptor-related protein 6
S1490xxx? Wnt pathway, development., cancer Zeng et al. (2005); Mi et al. (2006); Niehrs
and Shen (2010)S1590xxx?
T1572xxx?
TSC2 (tuberous sclerosis
2)/Tuberin
S1337xxx
S1341xxxS1345
Tumor suppressor Inoki et al. (2006)
CDC25 (cell division cycle) S76xxxT80 Cell cycle, cancer Kang et al. (2008)
RBL2/p130 S948xxxS952 Growth, cell cycle, cancer Litovchick et al. (2004)
S962xxxS966
S982xxxT986
Voltage dependent anion
channel
T51xxxT55 Apoptosis, cancer Pastorino et al. (2005)
CTPS (cytidine
triphosphate synthetase
S571xxxS575 Cell growth, cancer Higgins et al. (2007)
Mdm2 (murine double
minute 2)
S240xxxS244 Growth Kulikov et al. (2005)
S254xxxS258
Calcipressin/RCN1
(regulators of calcineurin)
S113xxxS117 Neuronal regulator of calcineurin, growth,
Alzheimer’s disease, down syndrome
Hilioti et al. (2004)
Gephyrin S270xxx? GABA transmission, neuronal functions Tyagarajan et al. (2011)
Mixed lineage kinase-3 S789xxx S793xxx? c-Jun and p38 MAPK pathways, apoptosis,
neurodegenerative disease
Mishra et al. (2007)
OMA-1 T339xxxT239 Oocyte maturation Nishi and Lin (2005)
p27Kip1 . . .?... Cell cycle regulator Surjit and Lal (2007)
Polypyrimidine
track-binding
protein-associated-splicing
factor (PSF)
T687 Alternative splicing, T cell function/activation Heyd and Lynch (2010)
Zinc ﬁnger CCHC
domain-containing protein
8 (Zcchc8)
T492xxx? RNA metabolism Gustafson et al. (2005)
SC35 . . .?... Alternative splicing Hernandez et al. (2004)
STRUCTURAL PROTEINS
DF3/MUC1 (high
molecular weight
mucin-like glycoprotein)
S40xxxS44 Wnt pathway, β-catenin, and E-cadherin
complex
Li et al. (1998)
Dynamin I T774xxxT778 Endocytosis, neuronal function Hong et al. (1998), Clayton et al. (2010)
Kinesin light chains (KLCs) S611xxxS615xxx? Axonal transport, mitosis, meiosis Morﬁni et al. (2002)
Microtubule-associated
protein 1B
S1260xxx? Neuronal functions Lucas et al. (1998), Trivedi et al. (2005),
Scales et al. (2009)T1265xxx?
S1388xxxS1392
Microtubule-associated
protein 2C
T1620xxx? Neuronal functions Sánchez et al. (2000)
T1623xxx?
Tau S208xxxT212 Microtubule stabilization, neuronal functions,
Alzheimer’s disease
Hanger et al. (1992), Yang et al. (1993),
Woods et al. (2001), Cho and Johnson
(2004)
T231xxxT235xxx?
S396xxx?
S404xxx?
Paxillin S126xxxS130 Cell adhesion and migration Cai et al. (2006)
Collapsin response
mediator protein 2
T509xxxT514xxx Neuronal functions, axonal growth, neuronal
polarity, Alzheimer’s disease
Cole et al. (2004b), Yoshimura et al. (2005)
S518xxxS522
Collapsin response
mediator protein 4
T509xxxT514xxx Neuronal function, axonal growth Cole et al. (2004b), Alabed et al. (2010)
S518xxxS522
(Continued)
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Table 1 | Continued
Substrate name GSK-3′s
phosphorylation site
(in bold) S/TxxxS/T
Biological process/relevance
to disease
Reference
Neural cell adhesion
protein (NCAM)
. . .?... Cell–cell adhesion, neurite outgrowth,
synaptic plasticity, learning, and memory
Mackie et al. (1989)
Neuroﬁlament L S502xxxS506xxx? Cell cytoskeleton, axonal growth, axonal
diameter
Guan et al. (1991);Yang et al. (1995), Sasaki
et al. (2002)S603xxx?
Neuroﬁlament M S666xxx?
Neuroﬁlament H S493xxx?
Ninein . . .?... Centrosomal functions, brain development,
tumorigenesis
Hong et al. (2000), Howng et al. (2004)
Telokin kinase-related
protein
S15xxx? Stabilization of smooth muscle myosin
ﬁlaments
Krymsky et al. (2001)
CLIP-associated protein 1
(CLASP 1)
. . .594–614. . .. Neuronal functions Wittmann and Waterman-Storer (2005),
Kumar et al. (2009)
CLASP 2 (CLIP-associated
protein 2)
S533xxxS537xxxS541 Cell migration, neuronal function Watanabe et al. (2009)
Focal adhesion kinase S722xxxS726 Cell cycle, survival, migration, cancer Bianchi et al. (2005)
Microtubule
afﬁnity-regulating
kinase-2/PAR-1
S212xxx? Neuronal function, axonal growth Kosuga et al. (2005), Timm et al. (2008)
Polycystin 2 S76xxxS80 Growth, survival, polycystic kidney disease Streets et al. (2006)
Dystrophin . . .?... Cytoskeleton of muscle ﬁbers Michalak et al. (1996)
Stathmin/oncoprotein 18
(STMN1)
S31xxx? Microtubule polymerization and dynamics Moreno and Avila (1998)
von Hippel–Lindau (VHL) S68xxxS72 Oxygen sensor, tumor of CNS, kidney, eyes Hergovich et al. (2006)
TRANSCRIPTION FACTORS
β-catenin S33xxxS37xxx Wnt pathway, development, cancer Yost et al. (1996), Ikeda et al. (1998)
T41xxxS45
δ-catenin T1078 Cell adhesion Oh et al. (2009)
CCAAT/enhancer-binding
protein αC/EBPα)
T222xxxT226xxx Cell proliferation, growth, differentiation Ross et al. (1999), Liu et al. (2006)
C/EBPβ
(CCAAT/enhancer-binding
protein β)
T179xxxS184xxxT188 Cell proliferation, growth, differentiation Tang et al. (2005), Zhao et al. (2005)
S177xxxS181xxx
S185xxxT189xxx
Cyclic AMP response
element-binding protein
(CREB)
S129xxxS133 Metabolism, neuronal function, memory
formation, diabetes
Fiol et al. (1994), Bullock and Habener
(1998)
GATA4 . . .2–116. . . Embryogenesis, myocardial differentiation
and function
Morisco et al. (2001)
. . .2–205. . .
Hypoxia-inducible factor-1 S551xxxT555xxx? Growth, cancer Mottet et al. (2003), Flugel et al. (2007)
S589xxx?
Heat shock factor-1 (HSF1) S303xxxS307 Stress (heat) response Chu et al. (1996)
c-Myc S62xxx? Growth, cancer, oncogenes Saksela et al. (1992), Sears et al. (2000)
L-myc T58xxxS62
N-myc downstream
regulated gene 1
T342xxxT346 Stress and hormone response, cell growth
and differentiation, cancer
Murray et al. (2004)
T352xxxT356
T362xxxT366
c-Jun, Jun B, Jun D T239xxxT243 Growth and cancer Boyle et al. (1991), Nikolakaki et al. (1993),
Woodgett et al. (1993), Morton et al. (2003)
c-Myb T572xxx? Hematopoiesis, tumorigenesis. Kitagawa et al. (2009)
Nuclear factor of activated
T cells c (NFATc)
SP2 domain Immune system response Beals et al. (1997), Neal and Clipstone
(2001)SP3 domain
(Continued)
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Table 1 | Continued
Substrate name GSK-3′s
phosphorylation site
(in bold) S/TxxxS/T
Biological process/relevance
to disease
Reference
Nuclear factor κB (NF-κB) S468xxx? Stress response, immune response, synaptic
plasticity and memory, cancer, inﬂammation,
autoimmune diseases
Demarchi et al. (2003), Buss et al. (2004)
p65subunit S903xxxS907xxx?
precursorp105 of p50
subunit
Notch 1C . . .?... Development, cell–cell communication,
cancer.
Foltz et al. (2002), Espinosa et al. (2003)
p53 S33xxxS37 Cell cycle regulator, cancer. Turenne and Price (2001), Qu et al. (2004)
S315xxx?
S376xxx?
Snail S97xxx S101 Epithelial to mesenchymal transition
regulator
Zhou et al. (2004)
S108xxx S112xxx
S116xxxS120xxx?
Activator protein 1 (AP-1) . . .?... Differentiation, proliferation, apoptosis de Groot et al. (1993)
Glucocorticoid receptor T171xxx? Stress and immune response, development,
metabolism
Rogatsky et al. (1998)
Microphthalmia-associated
transcription factor
S298xxx Melanocyte and osteoclast development Takeda et al. (2000)
NeuroD . . .?... Central nervous system development Moore et al. (2002)
BCL-3 S394xxxS398 Growth and cancer Viatour et al. (2004)
Bmal1 S17xxxT21xxx? Circadian rhythm Sahar et al. (2010)
Rev-erb α S55xxxS59xxx? Circadian rhythm Yin et al. (2006)
Timeless . . .?... Circadian rhythm Martinek et al. (2001)
Clock S427xxxS431 Circadian rhythm Spengler et al. (2009)
SMAD1 . . .?... Embryonic pattern formation, TGFβ signaling Fuentealba et al. (2007)
SMAD3 T66xxx? TGFβ signaling, development, cancer Guo et al. (2008)
Neurogenin 2 (Ngn2) S231xxx? Neuronal function, motor neurons,
development
Ma et al. (2008)
S234xxx?
BCLAF1 (Bcl-2 interacting
transcriptional repressor)
S531xxx? Apoptosis, cancer Linding et al. (2007)
Myocardin S455xxxS459xxx Development, cardiac hypertrophy Badorff et al. (2005)
S463xxxS467xxx?
S624xxxS628xxx
S632xxxS636xxx?
Histone H1.5 T10 Chromosome condensation Happel et al. (2009)
Nascent polypeptide
associated complex
T159 Transcriptional coactivator, bone
development.
Quelo et al. (2004)
Nuclear factor E2-related
factor 2
. . .?... Antioxidant response, cell survival Salazar et al. (2006), Rada et al. (2011)
SKN-1 S393xxxS397 Oxidative stress, detoxiﬁcation An et al. (2005)
Sterol regulatory
element-binding protein
T426xxxS430xxx? Lipid and cholesterol metabolism Sundqvist et al. (2005)
MafA/RIPE3β1 . . .?... Regulates insulin gene expression in β cells
of pancreas, pancreatic development
Han et al. (2007)
negative limb of the circadian machinery. PER and CRY pro-
teins are classically thought to translocate into the nucleus to
inhibit CLOCK:BMAL1 mediated transcription, thereby closing
the negative feedback loop (reviewed in Sahar and Sassone-Corsi,
2009).
GSK-3 is expressed in the primary center of circadian rhythm
regulation – the suprachiasmatic nucleus (SCN) of hypothalamus
(Iitaka et al., 2005). GSK-3αmRNA is found at higher levels in the
mouse SCN than GSK-3β (Iwahana et al., 2004). The expression
of both GSK-3αprotein and the phosphorylated form of GSK-3
have a daily rhythm on the SCN, with peak expression of GSK-
3α at ZT5 (Iwahana et al., 2004). Lithium treatment reduces the
expression of GSK-3α in the SCN at CT5 and CT 11 (Iwahana
et al., 2004).
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Lithium has been shown to lengthen the period of circadian
rhythms in a wide range of experimental systems, including uni-
cellular organisms, insects, mice, and humans (Abe et al., 2000;
Iwahana et al., 2004; reviewed in Engelmann, 1988). The GSK-3
ortholog in Drosophila, Shaggy (Sgg), plays a central role in deter-
mining circadian period length in ﬂies (Martinek et al., 2001). For
example, mutation of GSK-3 in Drosophila causes period length-
ening (Martinek et al., 2001). Sgg (GSK-3) phosphorylates Time-
less and regulates nuclear translocation of the Period/Timeless
heterodimer (Martinek et al., 2001).
GSK-3 has also been demonstrated to phosphorylate and reg-
ulate the stability of “core” circadian rhythm genes in mammals.
GSK-3 together with another serine kinase, DYRK1A, phospho-
rylates CRY2 at Ser 557 and 553 (respectively) resulting in degra-
dation of CRY2 (Harada et al., 2005; Kurabayashi et al., 2010).
GSK-3 phosphorylates BMAL1 (Ser17/Thr21) and these events
control the stability of the proteins and the amplitude of circa-
dian oscillation (Sahar et al., 2010). Moreover, GSK-3 has been
found to phosphorylate Rev-erbα (Yin et al., 2006), as well as
Clock (Spengler et al., 2009). GSK-3 interacts with Per2 in vitro
and in vivo, phosphorylates Per2 in vitro and promotes nuclear
translocation of Per2 (Iitaka et al., 2005; Kaladchibachi et al.,
2007). Overexpression of GSK-3 caused a ∼2 h advance in the
phase of mPER2 (Iitaka et al., 2005). Genetic depletion of two
alleles of GSK-3β in combination with deletion of one allele of
GSK-3α in synchronized oscillating mouse embryonic ﬁbroblasts
(3/4 GSK-3α/β KO MEFs) resulted in a signiﬁcant delay in the
period of endogenous clockmechanism,particularly in the cycling
period of Per 2 (Kaladchibachi et al., 2007). In contrast, one study
revealed that siRNA knockdown of GSK-3β or treatment with
GSK-3 inhibitors (CHIR 99021 and 1-azakenpaullone) shortened
the circadian rhythm (Hirota et al., 2008); however, the same study
observed prominent period lengthening by lithium in another
experimental system (Hirota et al., 2008).Nevertheless,pharmaco-
logical inactivation of GSK-3 by a related molecule (kenpaullone)
induced a phase delay in Per2 transcription (Kaladchibachi et al.,
2007).
ANIMAL MODELS OF GSK-3
Several genetic approaches have been used to generate mutant
mice for GSK-3: conventional knockouts and knock-ins (all tis-
sues), conditional knockouts (tissue-speciﬁc), and transgenicmice
(Table 2). Use of mice harboring genetic inactivation or over-
expression of one or both of the GSK-3 genes has proven a
powerful means to study GSK-3 function in brain develop-
ment, morphology, neurogenesis, memory and learning, senso-
rimotor function, sociability, emotionality as well as depressive-
like animal behaviors. The listings below are not exhaustive
as they focus on publications describing ﬁndings relevant to
brain functions. There are many more investigating the role of
GSK-3 in other tissues (including mammary gland, liver, heart,
etc.).
Table 2 | Animal models of GSK-3.
Type of approach Mouse design Mouse name Characterized by (reference)
CONVENTIONAL
Knockout Deletion of exon 2 (ATP-binding
loop) of GSK-3α
GSK-3α KO MacAulay et al. (2007), Kaidanovich-Beilin et al.
(2009), Lee et al. (2011), Lipina et al. (2011)
Knockout Deletion of exon 2 (ATP-binding
loop) of GSK-3β
GSK-3β KO Hoeﬂich et al. (2000)
Knockout Deletion of exon 2 (ATP-binding
loop) of GSK-3β
GSK-3β HET Hoeﬂich et al. (2000), Beaulieu et al. (2004),
O’Brien et al. (2004), Beaulieu et al. (2008),
Bersudsky et al. (2008), Kimura et al. (2008)
TRANSGENIC
Knock-in Mutations GSK-3 αS21A, βS9A GSK-3α, β [S21A,S9A] KI McManus et al. (2005), Eom and Jope (2009),
Ackermann et al. (2010), Mines et al. (2010),
Polter et al. (2010)
CONDITIONAL
Double shRNA knockdown GSK-3α/β shRNA
(shGSK-3-dh+/ﬂox)×Nestin-Cre
Nestin-Cre/shGSK-3-dh+/Δ Steuber-Buchberger et al. (2008)
Conditional knockout GSK-3α/GSK-3β ﬂox/ﬂox ×Nestin-Cre Nestin-GSK-3α+ β KO Kim et al. (2009)
Double shRNA knockdown GSK-3β shRNA DG–GSK-3β knockdown
(shRNA)
Omata et al. (2011)
TRANSGENIC
Dominant-negative (DN) GSK-3β K85RGSK-3β×CamkII-tTA-Cre DN-GSK-3β Gomez-Sintes et al. (2007)
Overexpression of GSK-3β TetO GSK-3β×CamkII-tTA-Cre Tet/GSK-3β Lucas et al. (2001), Hernandez et al. (2002),
Engel et al. (2006), Hooper et al. (2007)
Overexpression of constitutively
active GSK-3β [S9A]
S9AGSK-3β in Thy-1 gene vector GSK-3β [S9A] Spittaels et al. (2000), Spittaels et al. (2002),
Prickaerts et al. (2006)
Overexpression of GSK-3β Xenopus GSK-3β×mouse prion
promoter MoPrP.Xho
PrpGSK-3βL56 and
PrpGSK-3βL64
O’Brien et al. (2011)
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CONVENTIONAL KO MICE
The ﬁrst GSK-3 gene to be knocked out was GSK-3β (Hoeﬂich
et al., 2000). These animals die late in development either due to
hepatic apoptosis (Hoeﬂich et al., 2000) or a cardiac patterning
defect (double outlet, right ventricle; Kerkela et al., 2008).
GSK-3β heterozygous (HET) mice are viable, morphologically
normal and have been tested extensively. These animals exhibit a
lithium-mimetic, anti-depressant-like state (Beaulieu et al., 2004;
O’Brien et al., 2004). Notably, the anti-depressant-like behav-
ior in GSK-3β HET mice effectively normalizes the depressive
behavior caused by serotonin deﬁciency (Beaulieu et al., 2008).
Exploratory activity in these animals is reduced although general
locomotion remains normal (O’Brien et al., 2004). GSK-3β HET
animals show reduced responsiveness to amphetamine treatment
(Beaulieu et al., 2004; O’Brien et al., 2004), but have increased
morphine-induced locomotion (Urs et al., 2011). Sensorimotor
function as well as coordination and balance are normal in GSK-
3βHET mice (O’Brien et al., 2004; Bersudsky et al., 2008). GSK-3β
HET mice demonstrate increased anxiety (Bersudsky et al., 2008)
and reduced aggressive behavior (Beaulieu et al., 2008). Recent
studies by Kimura et al. (2008) have revealed the importance of
GSK-3β in memory reconsolidation in adult brain. Mice heterozy-
gous for GSK-3β exhibit retrograde amnesia (Kimura et al., 2008).
These animals have reduced memory reconsolidation but normal
memory acquisition, suggesting that they might be impaired in
their ability to form long-term memories.
In contrast to GSK-3β null mice, animals lacking GSK-3α are
viable and exhibit improved insulin sensitivity and hepatic glyco-
gen accumulation on the ICR background (MacAulay et al., 2007).
However, these anti-diabetic properties are not signiﬁcant on the
C57BL6 background (Patel et al., 2011). Similar to GSK-3βHET
mice (Beaulieu et al., 2004, 2008; O’Brien et al., 2004), GSK-3α
mutants have decreased exploratory activity, decreased immobil-
ity time, and anti-aggression behavior (Kaidanovich-Beilin et al.,
2009). GSK-3α KO animals also have abnormal behavioral fea-
tures that are unique to mice lacking the GSK-3α gene, such as
decreased locomotion, increased sensitivity to environmental cues,
decreased social motivation, and novelty; impaired sensorimotor
gating, associativememory, and coordination (Kaidanovich-Beilin
et al., 2009). GSK-3α KO mice also exhibit decreased numbers
of Purkinje cells in the cerebellum (Kaidanovich-Beilin et al.,
2009), as well as decreased dendrite length and surface, but show
no changes in spine density in the frontal cortex (Lee et al.,
2011).
CONDITIONAL KNOCKDOWN MODELS
Two studies have employed shRNAknockdown to suppress expres-
sion of the two GSK-3 genes in mouse brain. Nestin-Cre was
employed to drive shRNA expression in the brain progenitor com-
partment by excising LoxP ﬂanked transcriptional stop sites. This
approach resulted in partial reduction of GSK-3α and β protein
levels (60 and 50%, respectively) in whole brain lysate (Steuber-
Buchberger et al., 2008). These mice have partial embryonic or
neonatal lethality (50% of expected offspring). The surviving
double-shGSK-3α and β knockdown animals exhibited ∼50% of
the body weight of littermate controls (Steuber-Buchberger et al.,
2008).
In an alternative approach, lentivirus-expressing short-hairpin
RNAs targeting GSK-3β were injected bilaterally into the hip-
pocampus to inactivate GSK-3β in the dentate gyrus (Omata
et al., 2011). These DG–GSK-3β knockdown mice showed
decreased immobility time in both forced swim and tail suspen-
sion tests (TST), while the locomotor activity of these animals
was unchanged (Omata et al., 2011). This technique achieved 30%
suppression of GSK-3β in the hippocampus, sufﬁcient to yield an
anti-depressant-like behavior in the mice (Omata et al., 2011).
DOMINANT-NEGATIVE MUTANTS
Dominant-negatively acting mutants interfere with the endoge-
nous proteins by soaking up downstream targets or upstream
regulators. This approach has been used to generate conditional
transgenic expression of a dominant-negative (DN) form of GSK-
3β in the brain (Gomez-Sintes et al., 2007). Mutation of a critical
residue involved in ATP-binding, Lys85, to Arg inactivates the pro-
tein kinase activity of GSK-3β (Dominguez et al., 1995). Double
transgenic mice were generated that expressed dominant-negative
GSK-3β in a tetracycline-repressible manner under control of
a promoter that is active in the postnatal forebrain (CamKIIα-
tTA×K85RGSK-3β). These DN–GSK-3β mice grew normally
and showed no evidence of tumor formation (Gomez-Sintes
et al., 2007). However, these animals exhibited increased lev-
els of apoptosis in the brain regions involved in motor control
as well as showing behavioral deﬁcits in motor coordination
(Gomez-Sintes et al., 2007). Suppression of the DN–GSK-
3 transgene by doxycycline administration restored normal
GSK-3 activity and resulted full reversal of the motor and
of the neuronal apoptosis phenotypes (Gomez-Sintes et al.,
2007).
OVEREXPRESSION OF GSK-3β
Overexpression of GSK-3β has been postulated to be embry-
onic lethal as viable transgenic animals show only modest lev-
els of the exogenously engineered gene (Brownlees et al., 1997).
Mice overexpressing GSK-3β in the forebrain have been gener-
ated by placing the transgene under the control of a tetracycline
response element that is induced by administration of doxycy-
cline (Lucas et al., 2001). These Tet/GSK-3β mice have decreased
levels of nuclear β-catenin, increased phosphorylation of tau in
Alzheimer’s disease-relevant epitopes (correlatedwith somatoden-
dritic accumulation of microtubule-unbound tau in hippocampal
neurons), increased neuronal cell death, and reactive astrocytosis
and microgliosis (Lucas et al., 2001). Behavioral characterization
of Tet/GSK-3β mice revealed that these animals have impaired
acquisition of reference memory in a novel object recognition
task (Engel et al., 2006) and impaired spatial learning (Hernandez
et al., 2002). Moreover, Tet/GSK-3βmice have reduced LTP induc-
tion, a deﬁcit that was rescued by chronic treatment with lithium
(Hooper et al., 2007). Thus, mice with conditional overexpression
of GSK-3 in forebrain neurons (Tet/GSK-3β) recapitulate aspects
of Alzheimer’s disease neuropathology such as tau hyperphospho-
rylation, apoptotic neuronal death, and reactive astrocytosis, as
well as spatial learning deﬁcits. Moreover, these sequelae can be
completely reverted by restoration of GSK-3 activity by silencing
of transgene expression indicating that these biological defects, at
Frontiers in Molecular Neuroscience www.frontiersin.org November 2011 | Volume 4 | Article 40 | 12
Kaidanovich-Beilin and Woodgett Regulation and functions of GSK-3 in the brain
least, may be responsive to therapeutic intervention (Engel et al.,
2006).
Transgenic mice have also been generated that overexpress a
mutant form of GSK-3β in which the inhibitory N-terminal phos-
phorylation site ismutated [S9A] (Spittaels et al., 2000, 2002). This
formof the kinase cannot be inhibited by agonists of pathways that
promote phosphorylation of this site (such as PI3K, cAMP, etc.).
Thesemice are characterized bymicrocephaly andhigher neuronal
density due to reduction of the volume of the somatodendritic
compartment (dendrites and cell bodies) of pyramidal neurons in
the cortex (Spittaels et al., 2002). The levels of MAP2 were also
signiﬁcantly decreased in the brain and spinal cord of GSK-3β
[S9A] mice (Spittaels et al., 2002). However, postnatal overexpres-
sion of this non-inhibitable form of GSK-3β in neurons did not
alter behaviors of the mice in terms of general cognition and aging
and they showed only a minor decline in psychomotor capability
(Spittaels et al., 2002). Subsequent characterization revealed that
mice with constitutive overexpression of GSK-3β [S9A] showed
hypophagia, reduced water consumption, increased general loco-
motor activity, and increasedASR (acoustic startle response; Prick-
aerts et al., 2006). GSK-3β [S9A] mice showed reduced immobility
times in the forced swim test (FST) but this is likely related to the
hyperactivity of these animals (Prickaerts et al., 2006). There were
no differences in baseline and stress-induced increases of plasma
adrenocorticotrophic hormone and corticosterone levels in GSK-
3β [S9A]mice (Prickaerts et al., 2006). Biochemical examination in
these animals revealed upregulation of Akt1 together with down-
regulation of PPP2R3A (regulatory subunit of PP2A) and GSK-3α
in the striatum, as well as increased brain-derived neurotrophic
factor (BDNF) in the hippocampus (Prickaerts et al., 2006). In
summary, mice overexpressing active GSK-3β [S9A] represent a
model for studying hyperactivity, hyperreactivity, and disturbed
eating patterns; aspects which recapitulate some of the symptoms
observed in the manic phase of bipolar disorder patients, ADHD,
and schizophrenia.
GSK-3α, βMUTANT KNOCK-IN MICE
As mentioned above, mutation of the N-terminal phosphory-
lation sites of GSK-3 renders the protein kinase insensitive to
inhibition by that mode of regulation (although the kinase
remains sensitive to Wnt regulation, for example). Mice have
been generated in which the phosphorylation sites of the endoge-
nous alleles have been replaced by non-phosphorylatable ala-
nine (GSK-αS21A, βS9A). Since serine phosphorylation of GSK-3
is increased by lithium, anti-psychotic drugs, anti-depressants,
etc., this model is attractive to use for studying the mecha-
nism of action of aforementioned drugs and related patholog-
ical conditions. GSK-αS21A, βS9A knock-in mice have normal
development and growth, with no signs of metabolic abnormal-
ities/insulin resistance (McManus et al., 2005). However, these
animals have a drastic (40%) impairment in neurogenesis, which
is not increased/rescued by co-administration of ﬂuoxetine and
lithium (Eom and Jope, 2009). Expression of vascular endothelial
growth factor (VEGF), but not BDNF,was reduced inGSK-αS21A,
βS9A knock-in mice, suggesting that a deﬁciency in external
support for neural precursor cells might contribute to impaired
neurogenesis (Eom and Jope, 2009).
GSK-αS21A, βS9A knock-in mice exhibited increased suscep-
tibility to hyperactivity and a heightened response to a novel
environment (Polter et al., 2010).Moreover, these animals revealed
increased susceptibility to amphetamine-induced hyperactivity,
which was partially reversed by chronic lithium administration
(Polter et al., 2010). Besides being sensitive to hyperactivity, these
knock-in mutant mice displayed mild anxiety, had increased
immobility time in FST and TST and were highly susceptible
to stress-induced depressive-like behavior (Polter et al., 2010). In
contrast, studies by another group revealed decreased immobil-
ity time in FST, indicating a phenotype less prone to depression
(Ackermann et al., 2010). LTD in the mutants was found to be
abnormal and emotion-associated memory was impaired (Polter
et al., 2010). The knock-in animals also demonstrated impaired
social preference (Mines et al., 2010). Additional studies revealed
increased curiosity in these animals, associated with less sensitivity
to application of chronic mild stress as well as decreased HPA axis
activity (Ackermann et al., 2010).
CONDITIONAL KNOCKOUT MOUSE MODELS
Alleles of GSK-3α and β have been generated inwhich exon 2 (con-
taining essential residues for ATP-binding) are ﬂanked by LoxP
(ﬂox) sites (Figure 1). Tissue-speciﬁc expression of Cre recombi-
nase allows selective excision of the critical exon and inactivation
of the allele(s). Combination of a ﬂoxed GSK-3β gene on a GSK-
3α null background has been employed to generate total GSK-3
nullizygous cells in the developing nervous system via nestin-Cre
mediated excision (Nestin-GSK-3α, βKO; Kim et al., 2009). Selec-
tive deletion of both GSK-3α and β in neural precursor cells
results in dramatic hyperproliferation of neuronal progenitors
along the entire rostrocaudal extent of the neuraxis. The prog-
enitor expansion was at the expense of neurogenesis, intermediate
neural progenitors, and post-mitotic neurons indicating effective
inhibition of the differentiation process (Kim et al., 2009). The
morphological abnormalities were accompanied by dysregulation
of β-catenin, Hedgehog and Notch signaling as well as loss of
polarity of cell division (Kim et al., 2009).
LESSONS LEARNED FROM COMPARING BETWEEN GSK-3 ANIMAL
MODELS
Ten different GSK-3 animal models have been described to date
(Table 2). All of them display some kind of neuroanatomical and
behavioral abnormalities (Tables 3–6). However some of them
have not been fully characterized yet and require further examina-
tions. Overall, analysis of different animal models supports in vivo
role of GSK-3 in the regulation of fundamental brain functions
(emotionality, sociability, learning andmemory, andneurogenesis,
etc.).
The differences in behavioral results between different GSK-
3 animal models may be accounted for by the alternative design
of the models, and/or by strain and gender differences, varying
methodology, and animal house-keeping environment.
Well described and presented is effect of genetic GSK-3 manip-
ulations on depressive-like phenotype in mice (Table 3). In
all three models, inactivation of GSK-3α or β genes (Table 3)
revealed anti-depressive phenotypes, supporting studies with
GSK-3 inhibitors. However, a similar effect was found in mice
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Table 3 | Emotionality behaviors of GSK-3 mutant mice.
Behavioral
test
Type of test GSK-3α
KO
GSK-3α
HET
GSK-3β
HET
GSK-3αβ
knock-in
GSK-3β [S9A]
overexpression
DG–GSK-3β
knockdown (shRNA)
Anxiety EPM  In females
only (1)
 (2, 3) Mild  (6)
O-maze  (11)
Light–dark box = In males (1)
Emotionality Open ﬁeld 5min  (Both
genders) (1)
Locomotor
activity
Open ﬁeld 30min  (1) = (10) = (4, 5, 2)  (6, 11)  (8) = (12)
Exploratory
activity/curiosity
Open ﬁeld 30min  (1)  (2, 5) = (6)  (8)
Light–dark box (11)
Depression-like
behavior
Learned
helplessness
Stress-induced  (6)
FST  (1)  (2, 4, 5)  (6),  (11)  (8)  (12)
TST  (1) (2, 4, 5)  (6)  (12)
Stress reactivity Stress
response (1),
corticosteroids
(1)
General  (11) = (6),
stress response (6),
body weight, food,
and ﬂuid intake (11), 
(11) = (6),
corticosteroids,
ACTH (11)
= Corticosteroids
(8)
, Increased; , decreased; =, same/no changes.
References for the comparison tables are: 1. Kaidanovich-Beilin et al. (2009), 2. Bersudsky et al. (2008), 3. Beaulieu et al. (2008), 4. Beaulieu et al. (2004), 5. O’Brien
et al. (2004), 6. Polter et al. (2010), 8. Prickaerts et al. (2006), 10. Lipina et al. (2011), 11. Ackermann et al. (2010), 12. Omata et al. (2011).
Table 4 | Sociability behaviors of GSK-3 mutant mice.
Type of behavior Type of the test GSK-3α KO GSK-3β HET GSK-3αβ KI
Sociability and social novelty Social interaction test  (1) Impaired social preference to Str2 (7)
Aggression Resident intruder  (1)  (Beaulieu et al., 2008)
, Decreased.
References for the comparison tables are: 1. Kaidanovich-Beilin et al. (2009), 7. Mines et al. (2010).
overexpressing GSK-3β (GSK-3β S9A mice; Table 3). The con-
tradictory result in GSK-3β S9A mice was explained by increased
locomotor activity in these animals,whichmay affect performance
in the FST and its interpretation.
It is important to mention that different GSK-3 animal models
have employed different “Cre” promoters. Activation of speciﬁc
“Cre” recombinases may happen at different stages of embryoge-
nesis (or after birth), thus may affect speciﬁc neuronal popula-
tions (post-mitotic or precursors), which may affect structure and
function of adult brain. For example, dominant-negative GSK-3β
and Tet/GSK-3βmice have been generated by using CamkIIα-Cre,
compare to GSK-3β S9A mice which have been created by using
Thy-1 gene promoter (Table 2).
Moreover, there are different approaches have been used to gen-
eratemicewith overexpression of GSK-3β gene. In all threemodels
with overexpression of GSK-3β, different constructs for GSK-3β
gene itself were used (Table 2): intact GSK-3β in Tet/GSK-3βmice
versus point mutated form of GSK-3β (S9A) in GSK-3β[S9A] ani-
mals. GSK-3 has complex mechanisms of regulation, thus, is it
likely that overexpression of wild type protein has different effects
on speciﬁc brain functions than Serine 9mutated forms of the pro-
tein, depending on the relative importance of “phosphorylation”
as the regulatory mechanism in speciﬁc brain process/stimulation
and structure.
Comparison between GSK-3α KO and GSK-3α+ β serine
phosphorylation site KI mice revealed similar impaired socia-
bility in both models, despite different genetic approaches being
used. These data indicate that both the protein level of GSK-3α as
well as serine phosphorylation of GSK-3 are important aspects for
neuronal circuits responsible for social interaction.
Moreover, studying and analyzing genetic animal models may
be used to make predictions about long-term usage of GSK-3
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Table 5 | Memory, informational process, pharmacology, coordination behaviors of GSK-3 mutant mice.
Type of
behavior
Type of
the test
GSK-3α
KO
GSK-3α
HET
GSK-3β
HET
GSK-3αβ
KI
GSK-3β [S9A]
overexpression
Tet/GSK-
3β
DN–
GSK-3β
Amphetamine
response
OF+ amp   (4)  (6)  (16)
Response to
morphine
OF+morph  (23)
Information
processing
PPI/ASR  PPI (1) = (10) = (2, 5) ASR (8)
LI  NPE in KO
(1)
= (10)
Long-term
memory
FC  (1) Impaired
memory
reconsolidation
(9)
 (6), Enhanced
emotion-
associated
memory
Passive avoidance = (1)
LTP/LTD abnormal LTD in
the ventral
hippocampus (6)
 (20)
Spatial memory Impaired (22)
Coordination,
balance
Rotarod  (1) = (2, 5)  (16)
Motor learning Rotarod = (1) = (2, 5)
, Increased; , decreased; =, same/no changes.
References for the comparison tables are: 1. Kaidanovich-Beilin et al. (2009), 2. Bersudsky et al. (2008), 4. Beaulieu et al. (2004), 5. O’Brien et al. (2004), 6. Polter et al.
(2010), 8. Prickaerts et al. (2006), 9. Kimura et al. (2008), 10. Lipina et al. (2011), 16. Gomez-Sintes et al. (2007), 20. Hooper et al. (2007), 22. Hernandez et al. (2002).
inhibitors (as therapeutic agents). For example, the well character-
ized GSK-3 inhibitor – lithium – has a diverse spectrum of effects
after long-term treatment of patients, including tremor and death
of Purkinje cells. Of note, similar changes in cerebellar structure
and functionwere observed inGSK-3αKOanddominant-negative
GSK-3β mice (Tables 5 and 6).
Thus, comparative analysis of different animal models may
be very informative, however critical and combinatory approach
needs to be used to make correct interpretation and right
conclusions.
PATHOGENESIS OF NEUROLOGICAL DISORDERS THOUGH
CROSSBREEDING OF GSK-3 MUTANT MICE AND OTHER
NEUROLOGICAL MUTANTS
To study the role of GSK-3β in the pathogenesis of Alzheimer’s
disease, particularly with respect to the mechanism of tauopathy,
double transgenic mice have been generated by inter-breeding
mice overexpressingGSK-3β [S9A]with transgenicmice that over-
express the longest isoform of human protein tau (Spittaels et al.,
1999, 2000). Biochemical examination of brain and spinal cord
extracts from double transgenic mice revealed that the amount of
protein tau associated with microtubules was reduced compared
to mice harboring only hTau40 (Spittaels et al., 2000). Moreover,
unbound tau protein was hyperphosphorylated suggesting that
additional phosphorylation of tau in the double transgenic mice
reduces its binding capacity to microtubules, but fails to cause tau
ﬁlament formation (Spittaels et al., 2000). Importantly, virtually all
of the pathological defects observed in the hTau40 transgenic mice
(Spittaels et al., 1999) were rescued by the mild overexpression of
GSK-3β, such as the reduction by about an order of magnitude of
the number of axonal dilations in the brain and spinal cord, the
reduction in axonal degeneration and muscular atrophy, as well
as the alleviation of most motoric complication (Spittaels et al.,
2000).
DISC1 (Disrupted-in-Schizophrenia-1) is one of the best char-
acterized genetic risk factors for schizophrenia (reviewed in Harri-
son andWeinberger, 2005; Chubb et al., 2008; Brandon et al., 2009;
Jaaro-Peled et al., 2009).One breakpoint of a chromosomal t (1;11)
(q42.1;q14.3) translocationhas been identiﬁedwithinDISC1gene,
which co-segregates in a Scottish family with major mental illness,
including schizophrenia, bipolar disorder, and major depression
(Millar et al., 2000; Blackwood et al., 2001). DISC1 has been
demonstrated to play a role in essential brain functions from
embryonic development through to adulthood (reviewed in Jaaro-
Peled et al., 2009), such as neurogenesis, neuronal migration, neu-
rite outgrowth, spine development, neurotransmitter signaling,
cytoskeletal organization, cell cycle, signal transduction, intracel-
lular transport/exocytosis, etc.(reviewed in Chubb et al., 2008;
Brandon et al., 2009; Jaaro-Peled et al., 2009). DISC1 appears to act
as a coordinating hub or scaffold protein and hasmultiple intracel-
lular interacting proteins including GSK-3 (Camargo et al., 2007;
Mao et al., 2009; Lipina et al., 2011).
GSK-3 acts as an important downstream component in the eti-
ology of schizophrenia (reviewed in more detail elsewhere in this
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Table 6 | Neurogenesis, anatomical changes, biochemical, histological, and molecular characterizations of GSK-3 mutant mice.
Type of
analysis
Type of test GSK-3α KO Tet/GSK-3β GSK-3αβ KI GSK-3β [S9A]
overexpression
Nestin-GSK-
3αβ KO
DN–GSK-3β
Neuro
genesis
BrdU [3H]
thymidine
incorporation

Proliferation
(14)
= Proliferation (8)  Proliferation
(15),  differ-
entiation (15)
Apoptosis
necrosis
TUNEL,
caspase IHC

Apoptosis
(17)
=
Apoptosis
(14)
= Apoptosis (18), =
necrosis (18)
 Apoptosis
(16)
Neuro
anatomical
changes
MRI  Cerebellum
(1)
 Cerebellum,
cerebrum,
hippocampus, cortex
(18)
Histology  Dendrite
length and
surface area in
the frontal
cortex (12), = in
spine density
(12), = dendritic
arborization (12),
Purkinje cells
(1)

Microgliosis
(17), = tau
ﬁbrils (17,
22)
 Neuronal density in
cortex (18), = number
of cortical neurons (18),
 caliber of the
proximal and distal part
of the apical dendrites
(18),  size of the cell
body of pyramidal
neurons (18)
Tuj1, MAP2,
SMI32, NeuN
(15), Nestin,
Pax6 (15)
Brain weight  Brain (1)  Brain and spinal cord
(18, 8)
Biochemical
molecular
Western blot
RTPCR
 pTau (17),
 nuclear
β-catenin
(17)
 VEGF
(14), =
BDNF (14)
MAP2 (18),  pTau in
old mice (19), GSK-3α,
PPP2R3A and Akt1
in striatum (8), BDNF
in hippocampus (8)
 β-catenin, Axin,
c-jun, Gli1, Gli2,
Patched, Hes1,
Hes5, NICD,
c-myc, N-myc (15)
pTau (16), =
β-catenin (16)
, Increased; , decreased; =, same/no changes.
References for the comparison tables are: 1. Kaidanovich-Beilin et al. (2009), 8. Prickaerts et al. (2006), 12. Omata et al. (2011), 14. Eom and Jope (2009), 15. Kim et
al. (2009), 16. Gomez-Sintes et al. (2007), 17. Lucas et al. (2001), 18. Spittaels et al. (2002), 19. Spittaels et al. (2000), 22. Hernandez et al. (2002).
Special Topic series). There are several lines of evidence supporting
the involvement of GSK-3 in the pathogenesis of schizophrenia.
Polymorphisms in GSK-3 genes have been associated with schiz-
ophrenia (Souza et al., 2008; Benedetti et al., 2010). Dysregulation
of the PKB/Akt/GSK-3 signaling pathway has been found in
subjects with schizophrenia (reviewed in Koros and Dorner-
Ciossek, 2007; Lovestone et al., 2007; Beaulieu et al., 2009; Frey-
berg et al., 2009). For example, phosphorylation of GSK-3β Ser9
is reduced in the peripheral lymphocytes and brains of schizo-
phrenia patients (Emamian et al., 2004). Drugs that inﬂuence
the DA and 5-HT systems indirectly affect the activity of GSK-
3 (this topic is reviewed in greater detail in another chapter
in this Special Topic series). In the dopaminergic system, anti-
psychotic, and psychotomimetic drugs alter GSK-3 function (Mai
et al., 2002; Svenningsson et al., 2003; Beaulieu et al., 2004;
Emamian et al., 2004; Li et al., 2007). Lithium is used to aug-
ment anti-psychotic treatment in schizophrenia patients (Kang
et al., 2004; Gould, 2006). Moreover, GSK-3 inhibitors can rescue
schizophrenia-like behaviors in mice (Beaulieu et al., 2004; Lipina
et al., 2011).
Several mouse models for Disc1 have been described (reviewed
in Jaaro-Peled et al., 2009). For example, overexpression of
the N-terminal portion of Disc1 in the dentate gyrus causes
interaction with GSK-3, suppressing activity, and perturbing abil-
ity to down-regulate the Wnt/β-catenin pathway resulting in pro-
liferation of neuronal progenitors (Mao et al., 2009). Treatment
with a GSK-3 inhibitor, SB216763 rescued the behavioral effects
of lentivirally induced DISC1 suppression in the adult dentate
gyrus (Mao et al., 2009).
An ENU-induced mutant of Disc1, Disc1-L100P, exhibits
schizophrenia-related behaviors in mice (Clapcote et al., 2007).
Pharmacological as well as genetic inactivation of one allele of
GSK-3α reverses pre-pulse inhibition (PPI) and latent inhibition
(LI) deﬁcits as well as normalizing the hyperactivity of Disc1-
L100P mutants (Lipina et al., 2011). In parallel to these observa-
tions, interaction between DISC1 and GSK-3α and β is reduced
in Disc1-L100P mutants (Lipina et al., 2011). At the histological
level, genetic inactivation of GSK-3α partially corrected neurite
outgrowth and spine development abnormalities in the frontal
cortex induced by the Disc1-L100p mutation (Lee et al., 2011).
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SUMMARY
The emergence of sophisticated animal models with tissue and
developmentally selective expression of GSK-3 has allowed direct
assessment of the roles of this protein kinase in a variety of
neurological processes and conditions. Clearly, the complexity of
brain development and disease pathogenesis requires the use of
animal models to examine the biological role of candidate com-
ponents and with the numbers of candidate genes for neurological
illness increasing, allows relatively rapid assessment of genetic
interactions through inter-breeding of variant alleles.
While GSK-3 was ﬁrst implicated in a neurological disorder
in 1992 through its capacity to phosphorylate residues on Tau
that are associated with neuroﬁbrillary tangles in AD, the poten-
tial importance of this kinase in brain function and disease took
off with the identiﬁcation by Klein and Melton of GSK-3 as a
direct target of lithium (Klein and Melton, 1996; Stambolic et al.,
1996). Since that time, there has been enormous expansion of
understanding of this protein kinase with respect to regulation,
roles in normal development, and in pathophysiology. However,
despite this tsunami of knowledge, there are many remaining
questions including the therapeutic reality of modulating GSK-
3 in these disorders. Since the beneﬁcial effects of lithium on
stabilization of bipolar disorder is achieved at serum levels that
reduce GSK-3 levels by only 25% (noting that there are likely
several other targets of this drug) and the behavioral pheno-
types of Disc1L110P mutations are alleviated by knocking out
only one allele of GSK-3α (Lipina et al., 2011), subtle drug mod-
ulation of GSK-3 may be sufﬁcient for therapeutic beneﬁt in
humans.
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